- Trials with a EudraCT protocol (680)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (126)
Query did not match any clinical trials.
| These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
| Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. | |
| Study title: Comparative Safety and lmmunogenicity Study of Diphtheria, Tetanus, Acellular Pertussis, Poliomyelitis Vaccine (DTacP-IPV) and Diphtheria, Tetanus, Whole-cell Pertussis, Poliomyelitis Vaccine (TETRACOQ) Given As a Second Booster to 4- to 7-Year-Old Children |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41420 |
| Study title: Comparative Safety and lmmunogenicity Study of Diphtheria,Tetanus, Acellular Pertussis, Poliomyelitis vaccine (DTacP-IPV) and Diphtheria, Tetanus, Poliomyelitis Vaccine (D.T. Polio) Administered as a Booster in Children Aged 8 to 12 years |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41421 |
| Study title: Comparative study of acellular and whole cell pertussis vaccines combined with diphtheria, tetanus and inactivated poliomyelitis type 1, 2, 3 vaccines in healthy infants (primary-immunisation and booster) |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41413 |
| Study title: Comparative study of the safety and immunogenicity of a Diphtheria Tetanus Acellular Pertussis and a Diphtheria Tetanus Whole Cell Pertussis vaccine in Senegalese infants |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41411 |
| Study title: Comparative, randomised, double-blind safety and immunogenicity study of the Mérieux two-component acellular pertussis vaccine and the Mérieux one-component vaccine in healthy adult volunteers |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41406 |
| Study title: Dose response study of a Diphtheria, Tetanus, acellular Pertussis (DTacP) vaccine in 3-month-old children |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41407 |
| Study title: Evaluation of the PMSV. Diphtheria, Tetanus, Acellular Pertussis Vaccine (DTacP) in Infants, during a NlAlD Multicenter Acellular Pertussis Trial. Comparative Study Between PMSV. DTacP and Two Conventional Whole Cell DTP Vaccines |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41409 |
| Study title: Immunogenicity and reactogenicity of two dosages of acellular pertussis vaccine compared with whole-cell pertussis vaccine at primary (2, 4 and 6 months of age) and booster (15-24 months and 4-6 years of age) immunisation |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41408 |
| Study title: Large Scale Safety Study of the DTacP-IPV (Acellular Tetracoq) Vaccine, Administered in Combination (one injection site) or in Association (two injection sites) with Haemophilus influenzae type b Vaccine (Act-HIB) for Primary and Booster immunisation. |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41415 |
| Study title: Open, Randomised, Comparative Trial of the lmmunogenicity and Safety of two Immunisation Schedules (2-34 months and 24-6 months of age) using Diphtheria, Tetanus, Acellular Pertussis, Polio (DTacP-IPV) Vaccine mixed with Haemophilus influenzae type b (Act-HI B) Vaccine. |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41417 |
| Study title: Randomised Double-Blind Study of the Relative Efficacy and Safety of a DT Acellular Pertussis Vaccine with Respect to a DTP Whole-Cell Vaccine Among Children of Rural Senegal (Niakhar) |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41412 |
| Study title: Randomised, Open Trial of the lmmunogenicity and Safety of Diphtheria, Tetanus, Acellular Pertussis (DTacP) Vaccine Associated or Combined with Act-HIB Vaccine Given at 2-4-6 or 3-4-5 Months in Healthy Infants |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41418 |
| Study title: Safety and immunogenicity of a Diphtheria, Tetanus, acellular Pertussis, enhanced inactivated trivalent Poliovirus vaccine administered separately or combined with Haemophilus influenzae type b vaccine, to healthy Chilean Infants |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41416 |
| Study title: Safety and Immunogenicity of P.M. SV. Diphtheria, Tetanus, Acellular Pertussis, Polio (DTacP-IPV) Vaccine Given Mixed or Separately with Haemophilus influenzae type b (Act-HIBB) Vaccine, as a Primary Series. Comparison of Three Lots of DTacP-IPV Vaccine Given Combined or Separately with Act-HIB. |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41414 |
| Study title: Study of Safety and lmmunogenicity After Simultaneous Administration of DTacP-IPV Il Act-HIB Vaccine and ROR VAX (MMR) Vaccine in 14- to 16-Month-Old Toddlers |
| Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41419 |
| Study title: DTPa-HBV-IPV-020 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41517 |
| Study title: DTPa-HBV-IPV-055 Infanrix hexa |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41510 |
| Study title: DTPa-HBV-IPV-063 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41511 |
| Study title: DTPa-HBV-IPV-070 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41512 |
| Study title: DTPa-HBV-IPV-075 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41513 |
| Study title: DTPa-HBV-IPV-083 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41514 |
| Study title: DTPa-HBV-IPV-088 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41518 |
| Study title: DTPa-HBV-IPV-093 |
| Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41515 |
| Study title: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Leung TWT et al. Cancer, January 15, 2002, 421-7 |
| Active substance: FLUOROURACIL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 28272 |
| Study title: Fibrolamellar hepatocellular carcinoma in children and adolescents. Katzenstein HM et al. Cancer. 2003 Apr 15;97(8):2006-12 |
| Active substance: FLUOROURACIL |
| Study summary document link (including results): 12673731.pdf |
| View full study record |
| Document reference: 28303 |
| Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication] |
| Active substance: Mucosa compositum |
| Study summary document link (including results): |
| View full study record |
| Document reference: 40075 |
| Study title: Open Label, Multicenter, Phase IIIB, Follow up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis and Inactivated Poliovirus Antigens one Month after the 4th Hexavac® Vaccination in Healthy Children, who Participated in the NeisVac-C Non-Interference Study 216 |
| Active substance: N. meningitidis group C polysaccharide conjugated to tetanus toxoid adsorbed on Al3+ |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41293 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43096 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43124 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43182 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43192 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43202 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43217 |
| Study title: Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226.Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43100 |
| Study title: Hepatocellular carcinoma in children and adolescents: Results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. Katzenstein HM et al. J Clin Oncol. June 15, 2002, 2789-97 |
| Active substance: FLUOROURACIL |
| Study summary document link (including results): 12065555.pdf |
| View full study record |
| Document reference: 28270 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43227 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43237 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43247 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43319 |
| Study title: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcninoma. Zhang Z, Wu M, Liu Q. Chin J Oncol. July 6, 1999, 214-6 |
| Active substance: FLUOROURACIL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 28279 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: JMeza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: J |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43328 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43337 |
| Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
| Active substance: TAMOXIFEN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 43347 |
| Study title: Open label, randomised comparative assessment of the immunogenicity and reactogenicity of SmithKline Beecham's (SB's) diphteria/tetanus/acellular pertussis (DTPa) vaccine and SB's Hib with commercially available diphtheria/tetanus/whole cell pertussis (DTPw) and SB's Hib. Vaccines to be combined in the same syringe and administered to healthy infants as three consecutive doses at 2, 3 and 4 months of age. |
| Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41137 |
| Study title: EUV07: A phase III, open, randomized, controlled, primary vaccination study to assess the immunogenicity and the safety of CP20/20/5/3DT-IPV-PRP~T and ACTAcel given concomitantly with OPV vaccine and TETRAct-Hib given concomitantly with OPV vaccine at 6, 10, 14 weeks of age. All infants receiving hepatitis B vaccine (Recomvax B) at 0, 6, 14 weeks of age EUV06: Safety and immunogenicity of hepatitis B vaccine distributed by Aventis Pasteur Korea administered at 0-1-6 months when given in association with three Aventis Pasteur pertussis combination (1 whole cell and 2 acellular) vaccines administered at 2, 4 and 6 months in Mexican infants |
| Active substance: Hepatitis B Surface Antigen |
| Study summary document link (including results): |
| View full study record |
| Document reference: 47181 |
| Study title: Clinical study to assess the immunological memory induced by a primary course using different formulations of Hib conjugate vaccines in several combinations with acellular pertussis vaccines by giving one dose of unconjugated PRP co-administered with SB Biologicals¿ DTPa-HBV combined vaccine at 12-24 months of age in infants primed in study DTPa-HBV-037. |
| Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41146 |
| Study title: Open, randomised, clinical study to evaluate the interference on the immunogenicity of vaccine antigens, when Haemophilus influenzae type b tetanus conjugate and combined diphtheria, tetanus, acellular pertussis vaccines are co-administered, either in one single or two separate injections as a primary vaccination course to healthy infants at 2, 4 and 6 months of age. |
| Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41136 |
| Study title: Open clinical study to assess the safety of SmithKline Beecham Biologicals' Haemophilus influenzae type b conjugate vaccine mixed with SmithKline Beecham Biologicals' diphtheria, tetanus, tricomponent acellular pertussis vaccine and administered in one single injection, given as a primary vaccination course to healthy infants at 3, 4 and 5 months of age. |
| Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41132 |
| Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, whole-cell pertussis, poliomyelitis vaccine (TETRACOQ®) given as a second booster to 4- to 7-year-old children |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41193 |
| Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, poliomyelitis vaccine (DT POLIO®) administered as a booster in children aged 8 to 12 years |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41197 |
| Study title: Concomitant administration of a Haemophilus influenzae type b - Hepatitis b vaccine with a diphtheria, tetanus, acellular pertussis, inactivated polio combination vaccine in healthy infants |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41191 |
| Study title: Diminution of the anti-polyribosylribito phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae Type b vaccine by concurrent inactivated poliovirus vaccination |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41205 |
| Study title: Large scale safety study of the DTacP-IPV {acellular TETRACOQ®) vaccine, administered in combination (one injection site) or in assocation two injection sites) with Haemophilus influenzae Type b vaccine (Act-HIB®) for primary and booster immunisation |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41203 |
| Study title: Randomised open trial of the safety and the immunogenicity of a combined dihtheria, tetanus, acellular pertussis and inactivated polio vaccine (DTacP-IPV) mixed with Haemophilus influenzae type b vaccine (Act-HIB®) given either at 3-5 and 12 or 2-4-6 and 13 months of age |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41190 |
| Study title: Safety and immunogenicity of a diphteria, tetanus, acellular pertussis, enhanced inactivated trivalent poliovirus vaccine administered separately or combined with Haemophilus influenzae type b vaccine, to healthy Chilean infants |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41188 |
| Study title: Safety and immunogenicity of PMSV diphtheria, tetanus, acellular pertussis, polio (DTacP-IPV) vaccine given mixed or separately with Haemophilus influenzae type b (Act-HIB®) vaccine, as a primary series. Comparison of three lots of DTacP-IPV vaccine given combined or separately with Act-HIB® |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41189 |
| Study title: Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen-to nineteen-month-old infants |
| Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41192 |
| Study title: Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129)Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129) |
| Active substance: IODINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 30291 |
| Study title: Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56)Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56) |
| Active substance: IODINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 30327 |
| Study title: Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267)Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267) |
| Active substance: IODINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 30258 |
